Stamford’s Sema4 plans to buy genomic testing firm GeneDx of Maryland in a deal that projects $350 million in revenue for the combined companies this year.
GeneDx specializes in rare disease diagnostic and exome sequencing services, with data on more than 300,000 clinical exomes, or the coding portions of genes, and over 2.1 million phenotypes. That data will bolster Sema4’s Centrellis health information platform and Traversa, its genomic analysis database.